FDA gets power to fine companies selling unsafe cell and tissue products.
H.R. 1082 — Shandra Eisenga Human Cell and Tissue Product Safety Act · Filed by John Moolenaar (R-MI) · 1 cosponsor · Introduced Feb 6, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
The bill tells the FDA to teach people about cell and tissue transplants. It tells the FDA to teach about the risks they carry. The FDA can fine companies up to $20,000 per violation. The cap is $10 million per case. The FDA must share data about inspections. The FDA must share how long approval takes. The FDA will hold public meetings to update its rules.
Who it affects
People who get cell and tissue transplants benefit from stronger safety rules. Companies that make or sell these products must follow stricter rules. Companies may face fines for breaking rules.
One thing to notice
The $10 million cap per case might not stop big companies from breaking rules. The bill asks the FDA to update rules with help from industry.
From the analysis of the bill text, linked under Primary records below.
Where it stands
1 cosponsor: 1 Democrats.
- Feb 6, 2025 — Introduced · Congress.gov: “Introduced in House”
- Feb 6, 2025 — Referred to House Committee on Energy and Commerce and Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Referred to the House Committee on Energy and Commerce”
- Apr 29, 2025 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
- Apr 29, 2025 — Reported out of committee · Congress.gov: “Ordered to be Reported by Voice Vote”
- Jun 23, 2025 — Passed the House · Congress.gov: “On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H2860-2861)”
- Jun 23, 2025 — Floor vote scheduled · Congress.gov: “Mr. Bilirakis moved to suspend the rules and pass the bill”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 groups reported lobbying about this bill. They filed 2 reports from Dec 2025 to Jun 2026.
Those reports show $300,000 in lobbying spending. Each report lists about 16 bills. So that money was not all for this bill.
More groups named this bill than 0% of bills with any report.
John Moolenaar, who sponsored the bill, received $573,600 from PACs for the 2026 election.
- University of Michigan — $300,000 in 2 reports
Lobbying is legal. These reports show who lobbied about this bill, not what changed.
Words to know
- cell and tissue products — Medical treatments made from human cells or body parts used to help sick or hurt people.
- FDA — The government agency that checks if medicines and medical products are safe.
- fines — Money a company must pay for breaking rules.
- lobbying — Trying to influence lawmakers about a bill. Companies and groups pay people to do this.
- PACs — Groups that collect money and give it to candidates for office.
- sponsored — To sponsor a bill is to introduce it in Congress and put your name on it.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (6,162 characters) on Jun 10, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 14,707 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-09-23.
“FDA gets power to fine companies selling unsafe cell and tissue products.” QuorumCivic. https://share.quorumcivic.app/bill/119/hr1082/simple Report an error